Results 301 to 310 of about 200,211 (350)

Genetic Variants in Oxidative Stress-Related Genes and Their Impact on Prognosis and Treatment Response in Chronic Myeloid Leukemia Patients. [PDF]

open access: yesInt J Mol Sci
Alves R   +11 more
europepmc   +1 more source

Low rates of endothelial cell dysfunction and transplant‐related mortality in 537 children receiving fludarabine–treosulfan conditioning for all transplant indications: A retrospective multicentre study on behalf of the UK Paediatric BMT group

open access: yes
British Journal of Haematology, EarlyView.
Thomas Altmann   +11 more
wiley   +1 more source

PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3. [PDF]

open access: yesCell Death Dis
Barik B   +7 more
europepmc   +1 more source

Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of allogeneic HSCT

open access: yes
British Journal of Haematology, EarlyView.
Atte K. Lahtinen   +15 more
wiley   +1 more source

Chronic Myeloid Leukemia [PDF]

open access: possibleNew England Journal of Medicine, 1999
Over the past twenty years, clinical and laboratory studies have led to important new insights into the biology of chronic myeloid leukemia. Basic science has defined the molecular pathogenesis of chronic myeloid leukemia (CML) as unregulated signal transduction by the Bcr-Abl tyrosine kinase.
openaire   +4 more sources
Some of the next articles are maybe not open access.

Related searches:

Chronic myeloid leukemia

Current Opinion in Hematology, 1997
Progress has been made in understanding BCR-ABL-positive leukemias. A new transcript (p230BCR-ABL) has been characterized that is associated with Ph-positive chronic neutrophilic leukemia. The ATM protein appears to be a regulator of ABL activity in response to irradiation damage.
John M. Goldman, Michael W. Deininger
openaire   +4 more sources

Asciminib in chronic myeloid leukemia

Drugs of Today, 2022
Despite the fact that, in the last years, life expectancy of chronic myeloid leukemia (CML) patients has reached that of the normal population, a significant proportion of CML patients is likely to fail treatment with first- or second-generation tyrosine kinase inhibitors (TKIs).
Assanto, Giovanni Manfredi   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy